Skip to search formSkip to main contentSkip to account menu
Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain
View on Elsevier
Pharmacological activities of optically pure enantiomers of the κ opioid agonist, U50,488, and its cis diastereomer: evidence for three κ receptor subtypes
View via Publisher
Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependence
View on Elsevier
Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences
View on Elsevier
Chronic haloperidol treatment up-regulates rat brain PCP receptors.
View on PubMed
Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that μ ligands are noncompetitive inhibitors of the δ cx opioid peptide binding site
View on Elsevier
A study of the effect of the irreversible delta receptor antagonist [D-Ala2,Leu5,Cys6]-enkephalin on delta cx and delta ncx opioid binding sites in vitro and in vivo.
TLDR
The findings suggest that when administered in vivo, DALCE fails to distribute uniformly throughout the brain, and that it therefore binds covalently to opioid receptors mostly in the periventricular regions.
View on PubMed
Evidence for four opioid kappa binding sites in guinea pig brain.
View on PubMed
beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
beta-Funaltrexamine (beta-FNA) is an alkylating derivative of naltrexone. Considerable data support its use as an irreversible mu receptor antagonist. However, pretreatment of rats with beta-FNA…
View on PubMed
Chronic administration of morphine and naltrexone up-regulate[3H][d-ala2,d-leu5]enkephalin binding sites by different mechanisms
View on Elsevier
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License